In the news logo


It’s in the news! The top stories and headlines around the diabetes community this week include new progress in the quest for oral insulin to treat type 1, a new study says a common type 2 diabetes drug may help those with serious heart condition, a look at teen brains and T1D, NSAID and type 2 and more!

Learn about the T1d Exchange: 

Check out Stacey’s book: The World’s Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here


Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners – they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.


Our top story.. very early on here, but some progress in oral insulin for type 1. A team at University of British Columbia has developed a different kind of tablet that isn’t made for swallowing, but instead dissolves when placed between the gum and cheek. This method delivered all the insulin to the liver without wasting or decomposing any insulin along the way. That’s a big change from earlier studies and methods. The oral tablets absorb after about half an hour and last for up to four hours.. long way to go, no human trials yet. The the lead researcher on this project has a father with type 1 .
The type 2 diabetes drug dapagliflozin might also be used to help people with heart failure. A new study at Brigham and Women’s Hospital showed that dapagliflozin – sold under the brand name Farxiga – reduced the risk of a cardiovascular death, or worsening heart failure, regardless of ejection fraction. Ejection fraction is a term that basically refers to how much blood is pumped out by the left ventricle of the heart each time it contracts. That’s important because this drug has already been shown to help people who have the reduced pumping. And that’s a lot more people. Big study here, more than 12-thousand people with lots of ages and races, benefits consistent throughout.
I hesitate to bring this study up, but it’s gotten a lot of attention this week. It shows tight control of blood sugar in teens with Type 1 diabetes may help reduce the disease’s damaging effects on the brain. But this small study from Nemours Children’s Health, Jacksonville and Stanford University School of Medicine didn’t release any numbers, n other words, it’s not clear what they mean by tight control or at what level they’re referring to for brain issues. Their findings to indicate that automated hybrid closed loop systems work really well and that better glucose control can actually improve brain structure and function in teens with type 1. I’ve reached out to this group and we’re working on getting more information in a future episode.

Better Blood Sugar Control in Teens May Limit Diabetes-Related Brain Damage

Very early on here.. but an Indiana startup says they have a potentially game changing type 1 drug in development. In T1D, the body’s immune system causes destruction of beta cells, and as a result, they eventually stop producing insulin. These researchers say their models show thy can take what were thought to be dead beta cells, which are actually sleeping beta cells, and increase their insulin secretion and, basically, get them back to a functional state.” They’re focusing on a calcium imbalance within the beta cell and designing molecules to correct that calcium imbalance, ultimately returning the pancreas to a healthy state. JDRF has given them a big grant for a two year project, hopefully getting them to clinical trials.

Startup awarded nearly $1M to advance diabetes drug

People with type 2 diabetes might face a substantially increased risk of heart failure if they take ibuprofen or some other type of nonsteroidal anti-inflammatory drug (NSAID), accord to a new Danish study.
Short-term NSAID use increased risk of hospitalization for heart failure by 43% in people with type 2 but no previous heart problems. This was a large but preliminary study presented at the European Society of Cardiology’s annual meeting. NSAIDs increased the risk of heart failure even more in type 2 diabetics who were 80 or older (78%) or who had high blood sugar levels (68%), the results showed. Those who’d never used an NSAID before had the worst reaction, with their heart failure risk nearly tripling. Type 2 diabetics should consult with their doctor before taking any pain medicine, the doctors said. Other types of pain meds — specifically acetaminophen (Tylenol) — should be safe for them to use.

Back to the news in a moment but first..
The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy.
The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to
We told you about The Human Trial, Watch this gripping new documentary about the brave men and women who volunteer to test a radical new treatment for type 1 diabetes. n 2011, Lisa Hepner and her husband Guy Mossman heard about a radical stem cell treatment for diabetes, a disease that shockingly kills more than five million people each year. Driven by a desire to cure Lisa of her own type 1 diabetes (T1D), the filmmakers were given unprecedented, real-time access to a clinical trial — only the sixth-ever embryonic stem cell trial in the world. What follows is an intimate journey with the patients and scientists who put themselves on the line to be first.
Now, in partnership with Beyond Type 1 & JDRF , they’re offering the film for free. You are urged to make a donation to JDRF when you click over, there is an option to select zero,
Next week we’ve got a great episode all about Omnipod 5 in the real world. I spoke to a panel of moms and a young adult using the system. And we’ve got Insulet’s Director of Medical affairs addressing the questions that come up. This past episode is with my son Benny, talking about what it was like to spend 8 weeks away at non diabetes camp without any remote monitoring from us.
Listen wherever you get your podcasts
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Leave a Reply